Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
P/E ratio for Zymeworks Inc. (ZYME)
P/E ratio as of 2023: -6.03
According to Zymeworks Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.03. At the end of 2022 the company had a P/E ratio of 4.12.
P/E ratio history for Zymeworks Inc. from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -6.03 |
| 2022 | 4.12 |
| 2021 | -5.10 |
| 2020 | -13.19 |
| 2019 | -11.87 |
| 2018 | -11.65 |
| 2017 | -15.51 |
| 2016 | -7.57 |
| 2015 | -13.45 |
| 2014 | -19.92 |